Weight loss with real-world doravirine use in the OPERA cohort: a US-based cohort study
In one of the first real-world analyses of weight changes among virologically suppressed individuals who switched to a DOR-containing regimen in the US, DOR was associated with statistically significant weight loss. Patterns of use of other antiretrovirals did not fully explain the observed weight loss. These findings are clinically meaningful given that most individuals included were overweight or obese at switch to DOR and that women were predominantly of perimenopausal or menopausal age.
Authors
- Michael Sension
- Y. Omar Whiteside (ORCID: https://orcid.org/0000-0002-7828-3018)
- Karam Mounzer (ORCID: https://orcid.org/0000-0001-8537-7103)
- Jennifer S Fusco (ORCID: https://orcid.org/0000-0003-1556-811X)
- Michael D. Osterman (ORCID: https://orcid.org/0000-0003-4302-6596)
- Laurence Brunet (ORCID: https://orcid.org/0000-0001-8467-4835)
- Gregory Fusco (ORCID: https://orcid.org/0000-0002-6834-784X)
- Ricky K Hsu
Institutions
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- AIDS Healthcare Foundation (US)
- Fayetteville State University (US)
- NYU Langone Health (US)
- Philadelphia Fight (US)
Publication Details
- Journal
- AIDS Research and Therapy
- Published
- 2025-06-21
- DOI
- https://doi.org/10.1186/s12981-025-00761-5
- Citations
- 2
- Primary Topic
- HIV-related health complications and treatments
- Type
- article
- Field-Weighted Citation Impact
- 4.51